News Focus
News Focus
Followers 13
Posts 436
Boards Moderated 0
Alias Born 07/28/2019

Re: Wiseman1 post# 227070

Friday, 11/15/2019 8:05:57 PM

Friday, November 15, 2019 8:05:57 PM

Post# of 447431
Good. But AMGN still doesn't have the topline synergy unless FDA drops statin in the label or AMGN acquires a statin maker. IMO, as long as Vascepa is only approved as an adjunct therapy to statin, the potential acquirers will be limited to the usual suspects, i.e., BPs who sell statin.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News